KalVista Pharmaceuticals
(NASDAQ) KALV
This security has been delisted. This page is retained for historical reference.
KALV News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowKALV Financials
Key Financial Metrics (TTM)
Gross Margin
92.03%
Operating Margin
-120.80%
Net Income Margin
-119.44%
Return on Equity
-1057.44%
Return on Capital
-115.43%
Return on Assets
-41.28%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$106.66M
Operating Income
-$140.01M
EBITDA
-$117.15M
Operating Cash Flow
-$56.27M
Capital Expenditure
-$279.00K
Free Cash Flow
-$56.55M
Cash & ST Invst.
$300.21M
Total Debt
$284.21M
KalVista Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$59.93M
N/A
Gross Profit
$55.95M
+452.1%
Gross Margin
93.37%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
275
N/A
Net Income
-$5.37M
+89.7%
EBITDA
-$3.24M
+93.5%
Quarterly Fundamentals
Total Cash
$300.21M
+60.0%
Total Debt
$284.21M
+4406.2%
Accounts Receivable
$11.30M
-25.4%
Inventory
$3.43M
N/A
Long Term Debt
$269.02M
+6112.9%
Short Term Debt
$15.19M
+668.3%
Return on Assets
-41.28%
N/A
Return on Invested Capital
-50.36%
N/A
Free Cash Flow
$45.52M
+213.8%
Operating Cash Flow
$45.36M
+212.4%